会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Therapeutic methods and compositions involving isoflavones
    • 涉及异黄酮的治疗方法和组合物
    • US07915308B2
    • 2011-03-29
    • US12177843
    • 2008-07-22
    • Graham Edmund KellyGeorge Eustace Joannou
    • Graham Edmund KellyGeorge Eustace Joannou
    • A61K31/35A61K31/045A61K31/445
    • A61K8/498A61K8/35A61K8/492A61K31/12A61K31/352A61K31/353A61K31/355A61K31/40A61K31/404A61K31/405A61K31/47A61K31/4745A61K2800/522A61Q7/00A61Q19/00A61Q19/08C07C45/46C07C45/673C12P7/26C12P17/04C12P17/10A61K2300/00C07C49/83C07C49/84
    • Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (1), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CO2RC where RC is as previously defined, or CORCORE where RC and RE are as previously defined, and where the two R5 groups are attached to the same group they are the same or different, R6 is H or hydroxy C1-10alkyl, X is preferably O, but may be N or S, and Y is (h) where R7 is H, or C1-10alkyl.
    • 描述了治疗方法,组合物和食品,其含有通式(1)所述的异黄酮化合物,其中Z为H,R 1为H,或其中RA为C 1-10烷基或氨基酸,R 2为H,OH的RACO 或ORB,其中RB是氨基酸,或CORA,其中RA如前所定义,W是H,A是H或OH,B选自(a),(b),(c)或W是H 并且A和B一起形成选自(d)或W,A和B的六元环,与它们相关的基团一起取代,包括(e)或W和A与其组合 它们相关联,包括(f)和B是(g)其中R 3是H,其中RA如前所定义的CORA,其中RC是C 1-10烷基的CO 2 C或其中R B如前所定义的CORB,R 4是H,CORD,其中RD 是H,OH,C 1-10烷基或氨基酸,其中RC如前所定义的CO 2 CORE,其中RE是H,C 1-10烷基或氨基酸,COOH,CORC,其中RC如前所定义,或CONHRE,其中RE是 像以前的defi R 5为H,其中RC如前所定义的CO 2 R C或其中RC和RE如前所定义的CORCORE,并且其中两个R 5基团连接至相同基团,它们相同或不同,R 6为H或羟基C 1 -10烷基,X优选为O,但可以为N或S,Y为(h),其中R 7为H或C 1-10烷基。
    • 6. 发明授权
    • Therapeutic methods and compositions involving isoflavones
    • 涉及异黄酮的治疗方法和组合物
    • US06649648B1
    • 2003-11-18
    • US09254026
    • 1999-08-05
    • Graham Edmund KellyGeorge Eustace Joannou
    • Graham Edmund KellyGeorge Eustace Joannou
    • A61K3135
    • A61K8/498A61K8/35A61K8/492A61K31/12A61K31/352A61K31/353A61K31/355A61K31/40A61K31/404A61K31/405A61K31/47A61K31/4745A61K2800/522A61Q7/00A61Q19/00A61Q19/08C07C45/46C07C45/673C12P7/26C12P17/04C12P17/10A61K2300/00C07C49/83C07C49/84
    • Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CO2RC where RC is as previously defined, or CORCORE where RC and RE are as previously defined, and where the two R5 groups are attached to the same group they are the same or different, R6 is H or hydroxy C1-10alkyl, X is preferably O, but may be N or S, and Y is (h) where R7 is H, or C1-10alkyl.
    • 描述了治疗方法,组合物和食品,其含有通式(I)所述的异黄酮化合物,其中Z为H,R 1为H,或其中RA为C 1-10烷基或氨基酸,R 2为H,OH 或ORB,其中RB是氨基酸,或CORA,其中RA如前所定义,W是H,A是H或OH,B选自(a),(b),(c)或W是H 并且A和B一起形成选自(d)或W,A和B的六元环,与它们相关的基团一起取代,包括(e)或W和A与其组合 它们相关联,包括(f)和B是(g)其中R 3是H,其中RA如前所定义的CORA,其中RC是C 1-10烷基的CO 2 C或其中R B如前所定义的CORB,R 4是H,CORD,其中RD 是H,OH,C 1-10烷基或氨基酸,其中RC如前所定义的CO 2 CORE,其中RE是H,C 1-10烷基或氨基酸,COOH,CORC,其中RC如前所定义,或CONHRE,其中RE是 像以前的defi R 5为H,其中RC如前所定义的CO 2 R C或其中RC和RE如前所定义的CORCORE,并且其中两个R 5基团连接至相同基团,它们相同或不同,R 6为H或羟基C 1 -10烷基,X优选为O,但可以为N或S,Y为(h),其中R 7为H或C 1-10烷基。
    • 8. 发明授权
    • Process for glucan preparation and therapeutic uses of glucan
    • 葡聚糖制备方法和葡聚糖的治疗用途
    • US06242594B1
    • 2001-06-05
    • US08894773
    • 1997-12-02
    • Graham Edmund Kelly
    • Graham Edmund Kelly
    • C07H100
    • A61Q17/04A61K8/73A61K31/716A61L26/0023A61Q19/004A61Q19/08C08B37/0024C12P19/04Y10S514/925Y10S514/928C08L5/00
    • A process for the production of &bgr;-3-(1,3)(1,6) glucan from a glucan containing cellular source is described, together with compositions and uses/methods of treatment involving glucan. The process of the invention comprises the steps of: (a) extracting glucan containing cells with alkali and heat, in order to remove alkali soluble components; (b) acid extracting the cells of step (a) with an acid and heat to form a suspension; (c) extracting the suspension obtained of step (b) or recovered hydrolyzed cells with an organic solvent which is non-miscible with water and which has a density greater than that of water separating the resultant aqueous phase, solvent containing phase and interface so that substantially only the aqueous phase comprising &bgr;-(1,3)(1,6) glucan particulate material remains; wherein the extraction with said organic solvent provides separation of glucan subgroups comprising branched &bgr;-(1,3)(1,6)-glucan, and essentially unbranched &bgr;-(1,3) glucan which is associated with residual non-glucan contaminents; and (d) drying the glucan material from step (c) to give microparticulate glucan.
    • 描述了从含葡聚糖的细胞来源生产β-3-(1,3)(1,6)葡聚糖的方法,以及涉及葡聚糖的组合物和用途/治疗方法。 本发明的方法包括以下步骤:(a)用碱和热提取含葡聚糖的细胞,以除去碱溶性组分; (b)用酸和热将酸步骤(a)的细胞萃取以形成悬浮液; (c)用与水不溶的有机溶剂提取步骤(b)获得的悬浮液或回收的水解细胞,其密度大于分离所得水相,含溶剂相和界面的水的密度,使得 基本上只剩下包含β-(1,3)(1,6)葡聚糖颗粒材料的水相; 其中用所述有机溶剂萃取提供葡聚糖亚组的分离,所述葡聚糖亚组包含与残留的非葡聚糖污染物相关的支链β-(1,3)(1,6) - 葡聚糖和基本上未分支的β-(1,3)葡聚糖; 和(d)干燥步骤(c)的葡聚糖材料,得到微粒葡聚糖。